CXCL13 and experimental autoimmune encephalomyelitis: In experimental autoimmune encephalomyelitis (EAE), a MS murine model, blocking CXCL13 with an antibody or knocking it out entirely still allowed onset of disease to occur normally, but severity was attenuated over time, as shown by lower mean clinical scores and less activated microglia (61).